Inivata: Addario Lung Cancer Medical Research Inst
Post# of 301275
Addario Lung Cancer Medical Research Institute and Inivata Announce Major Study of ctDNA Analysis in Early Stage Lung Cancer
InVision(TM) ctDNA liquid biopsy platform to be used to inform therapy following surgery of curative intent
San Carlos, CA, Research Triangle Park, NC, and Cambridge, UK, September 27, 2017 -- Addario Lung Cancer Medical Research Institute (ALCMI), a patient-founded not-for-profit global research consortium, and Inivata , a global clinical cancer genomics company utilizing an industry-leading liquid biopsy platform to transform patient care, today announce a new lung cancer study utilizing Inivata's InVision liquid biopsy platform.
The goal of the study is to use highly sensitive InVision analysis to determine the potential role for ctDNA in measuring minimal residual disease (MRD) in patients following surgical resection in non-small cell lung cancer (NSCLC) with a view to help identify those patients who are in need of further therapy, and also to explore the value of ctDNA in monitoring for relapse.
Bonnie Addario, lung cancer survivor and the founder of both the Bonnie J. Addario Lung Cancer Foundation and ALCMI, said, "It is studies like this that will help lung cancer patients as they continue the fight for survival. As a survivor, I believe that less invasive and more timely ways to detect and treat residual disease will truly benefit patients."
" We are pleased to partner on this study with Inivata and our global research consortium's leading academic and community cancer centers. Our investigators see great potential in using liquid biopsies and molecular testing to help support the clinician's selection of treatments specifically tailored for the individual patient," added Steven Young, ALCMI's president and COO.
The LIBERTI ( Li quid B iopsy in E arly Stage NSCLC R esected Lung T umor I nvestigation) study will recruit up to 500 patients across approximately 10 ALCMI member institutions in the U.S., led by co-principal investigators Drs. Ramaswamy Govindan, Professor of Medicine, and Daniel Morgensztern, Associate Professor, both at the Washington University School of Medicine in St. Louis. The study's primary objective is to correlate the presence of ctDNA following surgical resection with disease recurrence in NSCLC. Additional objectives include exploring the role of ctDNA in the ongoing monitoring of patients during and following therapies administered following surgery with a view to improving long term outcomes.
Dr. Govindan said, " The ability to monitor for cancer recurrence in NSCLC patients post-surgery, where existing tools are very poor, would be enormously beneficial for patients. It would potentially allow for earlier and better targeted treatment and could have a significant effect on patient outcomes. The sensitivity of liquid biopsy assays, and the fact that they can be used repeatedly with a simple blood draw, makes them ideally suited for use in this setting. " Prof. Clive Morris, Chief Medical Officer of Inivata, said, " This collaboration is part of our ongoing program to establish the clinical utility of our InVision liquid biopsy platform and to illustrate the clinical challenges it can solve for physicians. We are delighted to be working with ALCMI, an outstanding organization committed to improving the lives of patients with lung cancer via world-leading investigators on this important study." - Ends -
About the Addario Lung Cancer Medical Institute The Addario Lung Cancer Medical Institute (ALCMI, voiced as "Alchemy"), founded in 2008 as a 501c(3) non-profit organization by lung cancer survivor Bonnie J Addario, is a patient-centric, international research consortium driving research otherwise not possible. Working in tandem with its "partner" foundation, the Bonnie J. Addario Lung Cancer Foundation (ALCF), ALCMI powers collaborative initiatives in genetic (molecular) testing, therapeutic discoveries, targeted treatments and early detection. ALCMI overcomes barriers to collaboration via a world-class team of investigators from 26 member institutions in the USA, UK, and Europe, supported by dedicated, centralized research infrastructures such as standardized biorepositories and data systems. ALCMI directly facilitates research by combining scientific expertise found at leading academic institutions with patient access through its network of community cancer centers - accelerating novel research advancements to lung cancer patients. By providing access to critical masses of patient stakeholders, academic, community and industry researchers, ALCMI and ALCF are making progress towards shared goals of transforming lung cancer into a chronically managed disease by 2023.
About Inivata Inivata is a global clinical cancer genomics company utilizing a proprietary, industry-leading liquid biopsy platform to transform patient care. Using a simple blood test (liquid biopsy), the analysis of ctDNA is a new lower-cost, less invasive, highly sensitive method for oncologists to diagnose and monitor cancer progression and treatment. The InVision(TM) liquid biopsy platform, based on pioneering research from the Rosenfeld Lab at the Cancer Research UK Cambridge Institute (CRUK-CI), University of Cambridge, combines industry-leading sensitivity with a select multi-gene panel to provide clinically actionable information to clinicians. Inivata has established collaborations with world-leading cancer centers and academic institutions, and is partnering with pharmaceutical and biotechnology companies. The Company has a CLIA lab in Research Triangle Park, NC and laboratories in Cambridge, UK. For more information, please go to www.inivata.com . Follow us on Twitter @Inivata.
Media Contacts:
For ALCMI: Samantha Cummis Samantha@lungcancerfoundation.org +1 650-598-2857
For Inivata: Karen Chandler-Smith karen.chandler-smith@inivata.com +44 (0)7900 430235
Consilium Strategic Communications: Chris Gardner/Laura Thornton/ Rosie Phillips inivata@consilium-comms.com +44 (0)20 3709 570
(0)
(0)